Cost-effectiveness of sugemalimab plus chemotherapy as first-line therapy in advanced gastric cancer and gastroesophageal junction cancer.
At current prices, sugemalimab plus CAPOX is not cost-effective as a first-line treatment for advanced GC/GEJC in China. It is essential to adopt a combination of targeted patient selection, price negotiation, and broader PAP access to bring the ICER below the WTP threshold. These findings inform reimbursement negotiations and highlight the need for stratified pricing strategies to optimize accessibility in economically diverse populations.
Authors
- Zhengxiong Li (ORCID: https://orcid.org/0009-0000-6031-4755)
- Qiaoping Xu (ORCID: https://orcid.org/0000-0002-8327-735X)
- Jiaming Zhu (ORCID: https://orcid.org/0009-0003-0176-3069)
Institutions
- Zhejiang Chinese Medical University (CN)
- Xuzhou Medical College (CN)
- Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine (CN)
- Hangzhou Medical College (CN)
- Hangzhou Cancer Hospital (CN)
Publication Details
- Journal
- Annals of Medicine
- Published
- 2025-12-09
- DOI
- https://doi.org/10.1080/07853890.2025.2583551
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00